Table 1.
Subjects' clinical characteristics at baseline.
| Placebo (25) |
Raloxifene (50) |
Tamoxifen (50) |
|
|---|---|---|---|
| Age (Lower-upper quartile) |
44 (42-47) |
46 (42-49) |
45 (41-49) |
| Age at menarche (Lower-upper quartile) |
13 (12-13) |
12 (12-13) |
12 (11-14) |
| Parity | 1 | 2 | 2 |
| Family history1 BC°- OC°° |
5 - 1 | 15 - 1 | 11 - 3 |
| Body mass index (Lower-upper quartile) |
22.9 (21.7-26.2) |
22.2 (20.5-24.6) |
22.2 (20.3-25.2) |
| Smoking Never/former/current/ missing |
14/3/8/0 | 28/10/11/1 | 24/5/21/0 |
| Tumor size mm (Lower-upper quartile) |
22.0 (15-30) | 22.5 (15.0-28.5) | 21.5 (15.0-27.5) |
| Tumor grade 1/2/3/unknown2 |
7/7/5/6 | 3/23/7/17 | 3/22/8/17 |
| HER2 overexpression % No/yes |
96/4 | 98/2 | 94/6 |
| Luminal subtype % A/B HER2 neg/B HER2 pos |
36/60/4 | 20/78/2 | 27/67/3 |
1First or second degree relatives with °breast cancer (BC) or °°ovarian cancer (OC); 2not graded by the pathologist.